Analysis of 72 patients with colorectal high-grade neuroendocrine neoplasms from three Chinese hospitals

Table 1 Patient characteristics

Characteristic	Patients (n = 72)
Sex, n (%)
Male	52 (72.2)
Female	20 (27.8)
Age [yr, median (range)]	59.5 (18-82)
BMI (kg/m2, mean ± SD)	23.8 ± 3.4
Symptoms, n (%)
Hematochezia	37 (51.4)
Abdominal pain	23 (31.9)
Changes in bowel habits	23 (31.9)
Obstruction	12 (16.7)
Abdominal distention	5 (9.6)
Weight loss	3 (4.2)
Anemia	2 (2.8)
Carcinoid syndrome	0
Asymptomatic	2 (2.8)
Family history of cancer, n (%)
Yes	11 (15.3)
No	60 (83.3)
Unrecorded	1 (1.4)
History of colorectal polyps, n (%)
Yes	24 (33.3)
No	27 (37.5)
Unrecorded	21 (29.2)
Smoking history, n (%)
Yes	28 (38.9)
No	42 (58.3)
Unrecorded	2 (2.8)
Drinking history, n (%)
Yes	24 (33.3)
No	45 (62.5)
Unrecorded	3 (4.2)
Primary sites, n (%)
Rectum	46 (63.9)
Rectosigmoid junction	2 (2.8)
Sigmoid	5 (6.9)
Descending colon	4 (5.6)
Transverse colon	2 (2.8)
Ascending colon	9 (12.5)
Cecum	4 (5.6)
Distance of tumor from the anal verge [(for rectal carcinoma, n = 46), n (%)]
0-5 cm	28 (60.9)
5-10 cm	14 (19.4)
10-15 cm	2 (2.8)
Unrecorded	2 (2.8)
Tumor size [median (range), cm]	5.0 (1.0-15.0)
Tumor stage, n (%)
I	4 (5.6)
II	4 (5.6)
III	27 (37.5)
IV	37 (51.4)
Site of distant metastases, n (%)
Liver	27 (37.5)
Liver only	12 (16.6)
Distant lymph nodes	15 (20.8)
Peritoneum	5 (6.9)
Bone	5 (6.9)
Lung	1 (1.4)
Pancreas	1 (1.4)
Increase of pretreatment blood LDH, n (%)
Yes	10 (13.9)
No	29 (40.3)
Unrecorded	33 (45.8)

BMI: Body mass index; SD: Standard deviation; LDH: Lactic dehydrogenase.